Victoria Ortiz-Gutiérrez, División de Oncología Médica, Hospital Ángeles Puebla, Puebla, Puebla, México
Iván R. González-Espinoza, División de Oncología Médica, Hospital Ángeles Puebla, Puebla, Puebla, México
José M. Fernández-Rivero, División de Coloproctología, Hospital Ángeles Puebla, Puebla, Puebla, México
Antonio J. Hernández-Robles, División de Cirugía General y Coloproctología, UMAE HE Manuel Ávila Camacho, IMSS, Puebla, Pue., México
Edgar Grageda-Flores, Unidad de Cirugía General, Instituto de Seguridad y Servicios Sociales de los Trabajadores al Servicio de los Poderes del Estado de Puebla (ISSSTEP), Puebla, Puebla, México
Juan A. Villanueva-Herrero, Unidad de Fisiología Anorrectal, Servicio de Coloproctología, Hospital General de México Dr. Eduardo Liceaga, Ciudad de México, México
Jeziel Ordóñez-Juárez, Jefatura del Servicio de Coloproctología, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jal., México
Bertha Dimas-Sánchez, Jefatura del Servicio de Coloproctología, Hospital General de México Dr. Eduardo Liceaga, Ciudad de México, México
Mónica P. Hernández-Molina, División de Cirugía Oncológica, ISSSTEP, Puebla, Puebla, México
Carlos A. López-Bernal, Subdirección de Cirugía, Hospital de Especialidades del Centro Médico Nacional Manuel Ávila Camacho, IMSS, Puebla, Puebla, México

Objective: To evaluate diabetes mellitus type 2 (DM2) as an prognostic factor for progression-free survival (PFS) in patients with advanced colorectal cancer. Methods: A retrospective, cross-sectional, and comparative study was conducted through the review of 314 medical records for individuals with advanced colorectal cancer (stage IV). Fifty-four patients met inclusion criteria, divided into two groups according to DM2 status. Variables analyzed included clinical, demographic, biochemical, and treatment-related characteristics. Results: Most patients were male (66.6%), with a mean age of 64 years and average body mass index of 24.3 kg/m². Both groups exhibited common risk factors. The overall mean PFS was 6.48 months. Patients with Dm2 show more rapid progression, increased metastatic burden, poorly differentiated tumors, worse ECOG performance status, and higher progression rates despite similar treatments (PFS: 7.5 vs. 9.5 months). A positive correlation was observed between fasting glucose and carcinoembryonic antigen levels. Tumor progression was more frequently observed in patients treated with metformin alone. Conclusions: Although the limited sample size precluded robust statistical significance, the findings indicate that DM2 may be linked to poorer prognosis in advanced colorectal cancer. These results highlight the importance of metabolic control and further studies with larger populations.

Keywords: Colectomy. Total mesorectal excision. Diverticulitis. Colostomy. Minimally invasive surgical procedures.